Casirivimab-Imdevimab (REGN-COV2) for Mild to Moderate SARS-CoV-2 Infection in Kidney Transplant Recipients
Kidney Int Rep
.
2021 Nov;6(11):2900-2902.
doi: 10.1016/j.ekir.2021.08.032.
Epub 2021 Sep 6.
Authors
Esther C Liu
1
,
Jennifer H Lee
1
,
Angela Loo
1
,
Shawn Mazur
1
,
Sam Sultan
2
,
Meredith Aull
2
,
Jun B Lee
3
4
,
Thangamani Muthukumar
3
,
Choli Hartono
3
4
Affiliations
1
Department of Pharmacy, New York Presbyterian Hospital-Weill Cornell, New York, New York, USA.
2
Division of Transplant Surgery, Weill Cornell Medicine, New York, New York, USA.
3
Department of Transplantation Medicine, Weill Cornell Medicine, New York, New York, USA.
4
The Rogosin Institute, New York, New York, USA.
PMID:
34514186
PMCID:
PMC8418987
DOI:
10.1016/j.ekir.2021.08.032
No abstract available